Sign In
Buy EIGR
$1.73
+0 (+0%)
At Close: Aug 27, 2024
Starbucks To $94? Here Are 5 Other Price Target Changes For Wednesday
12:02pm, Wednesday, 07'th Sep 2022 Benzinga
Citigroup raised the price target on Starbucks Corporation (NASDAQ: SBUX) from $90 to $94. Citigroup analyst Jon Tower maintained a Neutral rating on the stock. Starbucks shares fell 0.1% to $84.50
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
09:16am, Wednesday, 07'th Sep 2022 Benzinga
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
IVERIC bio, Inc. (NASDAQ: ISEE) rose 66.3% to close at $15.70
Dow Tumbles Over 200 Points; ChannelAdvisor Shares Spike Higher
07:37pm, Tuesday, 06'th Sep 2022 Benzinga
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dro
Nasdaq Drops 100 Points; DWAC Shares Plummet
05:41pm, Tuesday, 06'th Sep 2022 Benzinga
U.S. stocks traded lower midway through trading, with the Nasdaq dropping over 100 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dropping aroun
Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session
05:36pm, Tuesday, 06'th Sep 2022 Benzinga
Gainers
HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partne
Bed Bath & Beyond, Eiger BioPharmaceuticals And Some Other Big Stocks Moving Lower On Tuesday
03:08pm, Tuesday, 06'th Sep 2022 Benzinga
ProKidney Corp. (NASDAQ: PROK) shares tumbled 31.3% to $7.01. ProKidney recently named Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations.
Eiger BioPharmaceuticals, Inc. (NAS
US Stocks Trade Lower; Dow Drops Over 100 points
02:05pm, Tuesday, 06'th Sep 2022 Benzinga
U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dropping around 3%, a
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call Transcript
08:23pm, Saturday, 06'th Aug 2022
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory - President & CEO Ingr
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
11:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
09:03pm, Thursday, 04'th Aug 2022
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
07:52am, Tuesday, 26'th Jul 2022
European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for th
Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?
01:40pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
02:30pm, Wednesday, 08'th Jun 2022
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the declin
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q1 2022 Results - Earnings Call Transcript
09:21am, Sunday, 08'th May 2022
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President-Corporate Affairs David Cory - Presid
Eiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates
11:25pm, Thursday, 05'th May 2022 Zacks Investment Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
